GLPG0187 (Standard)

GLPG0187 (Standard) is the analytical standard of GLPG0187 (HY-100506) . This product is intended for research and analytical applications. GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM[1]. GLPG0187 inhibits migrasome biogenesis without cytotoxicity[3].

Product Specifications

CAS Number

[1320346-97-1]

Target

Integrin; Reference Standards

Related Pathways

Cytoskeleton; Others

Field of Research

Cancer

Smiles

O=C(O)[C@H](CNC1=NC(C)=NC(N2CCC(C3=NC4=C(CCCN4)C=C3)CC2)=C1C)NS(=O)(C5=CC=C(OC)C=C5)=O

Molecular Formula

C29H37N7O5S

Molecular Weight

595.71

References & Citations

[1]van der Horst G, et al. Targeting of α (v) -integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011 Jun;13 (6) :516-25.|[2]Reeves KJ, et al. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int J Cancer. 2015 Apr 1;136 (7) :1731-40.|[3]Puzhong Lu, et al. Chemical screening identifies ROCK1 as a regulator of migrasome formation. Cell Discov. 2020 Aug 4;6 (1) :51.